Page 13 - Read Online

40. Katoh M, Katoh M. Notch signaling in gastrointestinal by cadherins and Ig-CAMs in cancer. Nat Rev Cancer
tract (review). Int J Oncol 2007;30:247-51. 2004;4:118-32.
41. Foulkes WD, Flanders TY, Pollock PM, Hayward NK. 56. Ha PK, Califano JA. Promotor methylation and inactivation
The CDKN2A (p16) gene and human cancer. Mol Med of tumor-suppressor genes in oral squamous-cell carcinoma.
1997;3:5-20. Lancet Oncol 2006;7:77-82.
42. Hata A. TGFbeta signaling and cancer. Exp Cell Res 57. Donninger H, Vos MD, Clark GJ. The RASSF1A tumor
2001;264:111-6. suppressor. J Cell Sci 2007;120:3163-72.
43. Wu RC, Wang TL, Shih IeM. The emerging roles of ARID1A 58. Gerson SL. MGMT: Its role in cancer aetiology and cancer
in tumor suppression. Cancer Biol Ther 2014;15:655-64. therapeutics. Nat Rev Cancer 2004;4:296-307.
44. Weaver JM, Ross-Innes CS, Shannon N, Lynch AG, 59. Vasavi M, Kiran V, Ravishankar B, Prabhakar B, Ahuja YR,
Forshew T, Barbera M, Murtaza M, Ong CA, Lao-Sirieix P, Hasan Q. Microsatellite instability analysis and its correlation
Dunning MJ, Smith L, Smith ML, Anderson CL, Carvalho B, with hMLH1 repair gene hypermethylation status in
O’Donovan M, Underwood TJ, May AP, Grehan N, esophageal pathologies including cancers. Cancer Biomark
Hardwick R, Davies J, Oloumi A, Apariscio S, Caldas C, 2010;7:1-10.
Eldridge MD, Edwards PA, Rosenfeld N, Tavaré S, 60. Clément G, Braunschweig R, Pasquier N, Bosman FT,
Fitzgerald RC, OCCAMS Consortium. Ordering of mutations Benhattar J. Methylation of APC, TIMP3, and TERT: A new
in preinvasive disease stages of esophageal carcinogenesis. predictive marker to distinguish Barrett’s oesophagus patients
Nat Genet 2014;46:837-43. at risk for malignant transformation. J Pathol 2006;208:100-7.
45. Rumiato E, Pasello G, Montagna M, Scaini MC, De 61. Schildhaus HU, Kröckel I, Lippert H, Malfertheiner P,
Salvo GL, Parenti A, Cagol M, Ruol A, Ancona E, Amadori A, Roessner A, Schneider-Stock R. Promoter hypermethylation
Saggioro D. DNA copy number profi le discriminates between of p16INK4a, E-cadherin, O6-MGMT, DAPK and FHIT in
esophageal adenocarcinoma and squamous cell carcinoma and adenocarcinomas of the esophagus, esophagogastric junction
represents an independent prognostic parameter in esophageal and proximal stomach. Int J Oncol 2005;26:1493-500.
adenocarcinoma. Cancer Lett 2011;310:84-93. 62. Jin Z, Hamilton JP, Yang J, Mori Y, Olaru A, Sato F, Ito T,
46. Jiang W, Kahn SM, Tomita N, Zhang YJ, Lu SH, Weinstein IB. Kan T, Cheng Y, Paun B, David S, Beer DG, Agarwal R,
Amplifi cation and expression of the human cyclin D gene in Abraham JM, Meltzer SJ. Hypermethylation of the AKAP12
esophageal cancer. Cancer Res 1992;52:2980-3. promoter is a biomarker of Barrett’s-associated esophageal
47. Aoki K, Taketo MM. Adenomatous polyposis coli (APC): neoplastic progression. Cancer Epidemiol Biomarkers Prev
a multi-functional tumor suppressor gene. J Cell Sci 2008;17:111-7.
2007;120:3327-35. 63. Tischoff I, Hengge UR, Vieth M, Ell C, Stolte M, Weber A,
48. Pekarsky Y, Zanesi N, Palamarchuk A, Huebner K, Croce CM. Schmidt WE, Tannapfel A. Methylation of SOCS-3 and
FHIT: from gene discovery to cancer treatment and prevention. SOCS-1 in the carcinogenesis of Barrett’s adenocarcinoma.
Lancet Oncol 2002;3:748-54. Gut 2007;56:1047-53.
49. Nelson HH, Wiencke JK, Gunn L, Wain JC, Christiani DC, 64. Rettori MM, de Carvalho AC, Longo AL, de Oliveira CZ,
Kelsey KT. Chromosome 3p14 alterations in lung cancer: Kowalski LP, Carvalho AL, Vettore AL. TIMP3 and
Evidence that FHIT exon deletion is a target of tobacco CCNA1 hypermethylation in HNSCC is associated with an
carcinogens and asbestos. Cancer Res 1998;58:1804-7. increased incidence of second primary tumors. J Transl Med
50. Mori M, Mimori K, Shiraishi T, Alder H, Inoue H, Tanaka Y, 2013;11:316.
Sugimachi K, Huebner K, Croce CM. Altered expression 65. Kuester D, Dar AA, Moskaluk CC, Krueger S, Meyer F,
of Fhit in carcinoma and precarcinomatous lesions of the Hartig R, Stolte M, Malfertheiner P, Lippert H, Roessner A,
esophagus. Cancer Res 2000;60:1177-82. El-Rifai W, Schneider-Stock R. Early involvement of
51. Hechtman JF, Polydorides AD. HER2/neu gene death-associated protein kinase promoter hypermethylation in the
amplifi cation and protein overexpression in gastric and carcinogenesis of Barrett’s esophageal adenocarcinoma and its
gastroesophageal junction adenocarcinoma: A review of association with clinical progression. Neoplasia 2007;9:236-45.
histopathology, diagnostic testing, and clinical implications. 66. Valentino L, Pierre J. JAK/STAT signal transduction:
Arch Pathol Lab Med 2012;136:691-7. regulators and implication in hematological malignancies.
52. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Biochem Pharmacol 2006;71:713-21.
Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, 67. Iwagami S, Baba Y, Watanabe M, Shigaki H, Miyake K,
Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK, Ishimoto T, Iwatsuki M, Sakamaki K, Ohashi Y, Baba H.
ToGA Trial Investigators. Trastuzumab in combination with LINE-1 hypomethylation is associated with a poor prognosis
chemotherapy versus chemotherapy alone for treatment among patients with curatively resected esophageal squamous
of HER2-positive advanced gastric or gastro-oesophageal cell carcinoma. Ann Surg 2013;257:449-55.
junction cancer (ToGA): A phase 3, open-label, randomised 68. Xu E, Gu J, Hawk ET, Wang KK, Lai M, Huang M,
controlled trial. Lancet 2010;376:687-97. Ajani J, Wu X. Genome-wide methylation analysis shows
53. Bandla S, Peters JH, Ruff D, Chen SM, Li CY, Song K, similar patterns in Barrett’s esophagus and esophageal
Thoms K, Litle VR, Watson T, Chapurin N, Lada M, adenocarcinoma. Carcinogenesis 2013;34:2750-6.
Pennathur A, Luketich JD, Peterson D, Dulak A, Lin L, 69. Dawson MA, Kouzarides T. Cancer epigenetics: from
Bass A, Beer DG, Godfrey TE, Zhou Z. Comparison of mechanism to therapy. Cell 2012;150:12-27.
cancer-associated genetic abnormalities in columnar-lined 70. Bojang P Jr, Ramos KS. The promise and failures of
esophagus tissues with and without goblet cells. Ann Surg epigenetic therapies for cancer treatment. Cancer Treat Rev
2014;260:72-80. 2014;40:153-69.
54. Baba Y, Watanabe M, Baba H. Review of the alterations in 71. Langer R, Mutze K, Becker K, Feith M, Ott K, Höfl er H,
DNA methylation in esophageal squamous cell carcinoma. Keller G. Expression of class I histone deacetylases (HDAC1
Surg Today 2013;43:1355-64. and HDAC2) in oesophageal adenocarcinomas: an
55. Cavallaro U, Christofori G. Cell adhesion and signalling immunohistochemical study. J Clin Pathol 2010;63:994-8.

6 Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 1 ¦ April 15, 2015 ¦